Nathalie Dubois-Stringfellow
Chief Development Officer
Other
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Sangamo Therapeutics, Inc (SGMOQ) | Chief Development Officer | $453,600 | $1,132,369 |
| 2023 | Sangamo Therapeutics, Inc (SGMOQ) | Senior Vice President, Chief Development Officer | $453,600 | $1,027,105 |
Earnings-call appearances
-
Sangamo Therapeutics, Inc Q1 FY2026 Earnings Call2026-05-14
Sangamo Therapeutics, Inc (SGMOQ)
-
Sangamo Therapeutics, Inc Q4 FY2025 Earnings Call2026-03-30
Sangamo Therapeutics, Inc (SGMOQ)
-
Sangamo Therapeutics, Inc Q3 FY2025 Earnings Call2025-11-06
Sangamo Therapeutics, Inc (SGMOQ)
-
Sangamo Therapeutics, Inc Q2 FY2025 Earnings Call2025-08-07
Sangamo Therapeutics, Inc (SGMOQ)
-
Sangamo Therapeutics, Inc Q3 FY2024 Earnings Call2024-11-12
Sangamo Therapeutics, Inc (SGMOQ)
-
Sangamo Therapeutics, Inc Q2 FY2024 Earnings Call2024-08-06
Sangamo Therapeutics, Inc (SGMOQ)
-
Sangamo Therapeutics, Inc Q1 FY2024 Earnings Call2024-05-09
Sangamo Therapeutics, Inc (SGMOQ)
-
Sangamo Therapeutics, Inc Q4 FY2023 Earnings Call2024-03-13
Sangamo Therapeutics, Inc (SGMOQ)
-
Sangamo Therapeutics, Inc Q3 FY2023 Earnings Call2023-11-01
Sangamo Therapeutics, Inc (SGMOQ)
-
Sangamo Therapeutics, Inc Q2 FY2023 Earnings Call2023-08-08
Sangamo Therapeutics, Inc (SGMOQ)
-
Sangamo Therapeutics, Inc Q1 FY2023 Earnings Call2023-04-26
Sangamo Therapeutics, Inc (SGMOQ)
-
Sangamo Therapeutics, Inc Q4 FY2022 Earnings Call2023-02-22
Sangamo Therapeutics, Inc (SGMOQ)
-
Sangamo Therapeutics, Inc Q3 FY2022 Earnings Call2022-11-03
Sangamo Therapeutics, Inc (SGMOQ)